Post-earnings recap
Reported
Wed, May 20, 2026
EPS actual
$-0.73
EPS est.
$-0.60
EPS surprise
-21.06%
1-day move
+35.26%
Immunovant's earnings report showed a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock surged by over 35%, indicating that investors may have reacted positively to other aspects of the company's performance or potential. The lack of revenue and guidance details leaves some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.73 | $-0.63 | -21.06% |
| Revenue | $0M | $0M | — |
No transcript is on record, and the analysis is based solely on numerical results.
Immunovant, Inc. is a biotechnology company focused on developing therapies for autoimmune diseases. With a market cap of $5 billion, it operates in the health care sector, which is currently seeing increased interest due to advancements in medical treatments and a growing demand for innovative therapies.
Last quarter
In Q3-2026, Immunovant reported an EPS of $-0.61, which was better than the expected $-0.72, resulting in a positive stock reaction of +12.43% the following day. The company continues to focus on its pipeline of therapies.
EPS beat streak
0Q
EPS beat rate
38%
Avg EPS surprise
-3.69%
Avg 1-day reaction
+4.47%
Analysts expect Immunovant to report a loss this quarter, but there is hope for a surprise given the company's recent performance. The stock has shown volatility around earnings, which could lead to significant price movements.
Bull case
If Immunovant beats EPS expectations, it could signal strong operational management and potentially boost investor confidence, leading to a positive stock reaction.
Bear case
A miss on EPS could reinforce concerns about the company's financial health and lead to a negative stock reaction, especially given the lack of revenue expectations.
Key metrics to watch
EPS
$-0.63Earnings per share (EPS) is crucial as it reflects the company's profitability and is a key indicator for investors.
Revenue
$0MWhile no revenue is expected this quarter, any updates on future revenue potential will be closely watched.
The print will turn on these.
Q1
Will the EPS come in better than the consensus estimate of $-0.63?
A positive surprise could indicate improved operational efficiency and boost investor sentiment.
Q2
What updates can the company provide regarding its pipeline and future revenue potential?
Any insights into upcoming products or partnerships could significantly impact future revenue expectations.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±8.9%
Why consensus could be wrong
The Street may be underestimating Immunovant's ability to improve its EPS, as recent operational efficiencies have not been fully recognized.
Supporting evidence
The company has a history of surprising on EPS, with a 38% beat rate in recent quarters.
Options pricing suggests a larger move than historical averages, indicating potential for a surprise.
Insider selling could reflect a strategic repositioning rather than a lack of confidence.
Key risk
If the EPS comes in better than expected, it could shift the narrative around the company's financial health.
Pre-commit to what would confirm each case.
The market is debating whether Immunovant can turn around its losses and provide a clearer path to profitability.
Bull confirmed if
An EPS of better than $-0.53 would confirm the bull case and suggest operational improvements.
Bear confirmed if
An EPS worse than $-0.73 would confirm the bear case and raise concerns about the company's financial health.
What the market is pricing for the move.
Implied Move
±14.5%
Historical Avg
±9.2%
The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.
Options are pricing ±14.5% while IMVT has averaged ±9.2% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
52.9%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$223,070.22
6,352 sh
2 insiders
Net
$223,070.22
Net selling
Most Active Insiders· 2 open-market trades
$119,589.66
Net selling
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Immunovant beats expectations, history suggests a positive reaction of about +4.5%, confirming that the company is on the right track.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
A miss could lead to a decline of around -1.18%, reflecting ongoing concerns about the company's financial stability.
The lines on the call that would change the story.
$103,480.56
Net selling
Recent Transactions
Oct 2, 2026 · @ $34.11
3,506 sh
$119,589.66
Sep 23, 2026 · @ $36.36
2,846 sh
$103,480.56
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.